ABBVIE

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 2013-01-01

Employees: -

Market Cap: $346B

Website: http://www.abbvie.com

Clinical Trials

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2015-12-29

Last Posted Date: 2018-10-17

Lead Sponsor: AbbVie

Target Recruit Count: 394

Registration Number: NCT02640547

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C Virus (HCV) Infection

Interventions: Drug: ABT-493/ABT-530
Drug: Placebo for ABT-493/ABT-530

First Posted Date: 2015-12-29

Last Posted Date: 2021-07-16

Lead Sponsor: AbbVie

Target Recruit Count: 304

Registration Number: NCT02640482

A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor

Phase 1

Withdrawn

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkin Lymphoma
Small Lymphocytic Lymphoma

Interventions: Drug: Duvelisib
Drug: Venetoclax

First Posted Date: 2015-12-29

Last Posted Date: 2016-07-26

Lead Sponsor: AbbVie

Registration Number: NCT02640833

Locations: 🇺🇸
Site Reference ID/Investigator# 148562, Harvey, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 147922, Chicago, Illinois, United States
🇺🇸
Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States

and more 7 locations

A Study Comparing Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Dosed With Daclatasvir in Adults With HCV Genotype 3 Infection

Phase 3

Completed

Conditions: Chronic Hepatitis C
Hepatitis C Virus
Genotype 3 Hepatitis C Virus

Interventions: Drug: ABT-493/ABT-530
Drug: Sofosbuvir
Drug: Daclatasvir

First Posted Date: 2015-12-28

Last Posted Date: 2021-07-30

Lead Sponsor: AbbVie

Target Recruit Count: 506

Registration Number: NCT02640157

Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary

Completed

Conditions: Chronic Hepatitis C

First Posted Date: 2015-12-22

Last Posted Date: 2019-07-26

Lead Sponsor: AbbVie

Target Recruit Count: 244

Registration Number: NCT02636608

The Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 4, 5, or 6 Infection (ENDURANCE-4)

Phase 3

Completed

Conditions: Hepatitis C Virus

Interventions: Drug: ABT-493/ABT-530

First Posted Date: 2015-12-22

Last Posted Date: 2021-07-13

Lead Sponsor: AbbVie

Target Recruit Count: 121

Registration Number: NCT02636595

Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis

Phase 3

Active, not recruiting

Conditions: Ulcerative Colitis

Interventions: Biological: Adalimumab

First Posted Date: 2015-12-16

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 101

Registration Number: NCT02632175

Locations: 🇺🇸
MNGI Digestive Health, P. A. /ID# 147294, Minneapolis, Minnesota, United States
🇵🇱
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego /ID# 147310, Wroclaw, Dolnoslaskie, Poland
🇵🇱
Instytut Centrum Zdrowia Matki Polki /ID# 169017, Lodz, Lodzkie, Poland

and more 13 locations

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate

Phase 3

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: Adalimumab
Drug: Placebo for Adalimumab
Drug: Placebo for Upadacitinib
Drug: Upadacitinib

First Posted Date: 2015-12-14

Last Posted Date: 2024-06-18

Lead Sponsor: AbbVie

Target Recruit Count: 1629

Registration Number: NCT02629159

Locations: 🇺🇸
Precision Research Org, LLC /ID# 143092, Miami Lakes, Florida, United States
🇺🇸
DM Clinical Research /ID# 151357, Tomball, Texas, United States
🇿🇦
Arthritis Clinical Research Tr /ID# 144874, Cape Town, Western Cape, South Africa

and more 367 locations

Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1

Completed

Conditions: Chronic Hepatitis C Virus

First Posted Date: 2015-12-14

Last Posted Date: 2020-02-24

Lead Sponsor: AbbVie

Target Recruit Count: 3043

Registration Number: NCT02629172

Locations: 🇯🇵
Mori Clinic /ID# 157489, Osaka, Japan
🇯🇵
Aichi Medical University Hosp /ID# 152220, Nagakute, Aichi, Japan
🇯🇵
Nagoya City University Hospital /ID# 153642, Nagoya-shi, Aichi, Japan

and more 385 locations

Real-World Outcome of Rheumatoid Arthritis Patients in Korea on Adalimumab

Completed

Conditions: Rheumatoid Arthritis

First Posted Date: 2015-12-11

Last Posted Date: 2019-03-22

Lead Sponsor: AbbVie

Target Recruit Count: 91

Registration Number: NCT02627924

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy